EGFR and non-small cell lung carcinoma: Although the third-generation EGFR-TKIs have been the favorable choice for treatment-naïve EGFR-mutated advanced NSCLC patients, the regimen of first- and second-generation EGFR-TKI upfront use followed by sequential third-generation EGFR-TKI treatment still remains an attractive option for both patients and clinicians.